Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
AB Science S.A. is a clinical-stage pharmaceutical company headquartered in Paris, France, founded in 2001. It specializes in the research, design, development, and marketing of innovative drugs targeting diseases with high unmet medical needs, particularly in oncology, inflammatory diseases, and neurological disorders. The company's lead compound, masitinib, is a highly selective tyrosine kinase inhibitor currently advanced in phase 3 clinical trials for conditions such as amyotrophic lateral sclerosis (ALS), indolent severe systemic mastocytosis, severe asthma, progressive multiple sclerosis, and metastatic castrate-resistant prostate cancer. AB Science also develops AB8939, a microtubule destabilizer for acute myeloid leukemia, and maintains a diversified pipeline with multiple late-stage programs. Notably, masitinib is already marketed in veterinary medicine as Masivet® in Europe since 2008 and Kinavet® in the USA since 2010 for canine mast cell tumors, providing recurring revenues and validating its therapeutic potential across species. Operating within the pharmaceuticals and biotechnology sector, AB Science S.A. bridges innovations in animal and human health, contributing to advancements in specialty drug manufacturing through rigorous international clinical studies and regulatory achievements.
€0.74
+€0.02 (+3.33%)
EOD Aug 14, 2026
54.43% operating margin is above average. ROIC at 2.70%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue grew 9.5%, steady but not accelerating. Free cash flow declined 1335% despite revenue growth, conversion is weakening.
Free cash flow declined 1335% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -€5M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€1M
▲ +9.5% YoY
Net Income (TTM)
-€2M
▲ +80.1% YoY
Op. Margin
54.43%
▲ +621.9pp YoY
ROIC
2.70%
▲ +28.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€5M
▼ -1335.4% YoY
Op. Cash Flow (TTM)
-€2M
▼ -569.8% YoY
Net Debt
€9M
Cash & Equiv.
€10M
3Y CAGR: +7.0%
Continue Research
AB Science (AB.XPAR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, AB Science scores 26/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
AB Science scores 26 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 54.4% operating margin and a 2.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AB.XPAR's valuation and scores 26/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.